---
title: "Zepbound (tirzepatide) in chronic weight management: Clinical trials questions"
description: "Clinical trials questions on Zepbound (tirzepatide) in chronic weight management, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results. Questions: How much weight do people lose on Zepbound (SURMOUNT-1)? Zepbound: how many people lose 5%, 10%, 15%, or 20% of their weight? How many people on Zepbound lose 25% or more of their body weight? Zepbound in type 2 diabetes: how much weight do people lose (SURMOUNT-2)? 7 further questions follow. 11 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/zepbound--chronic-weight-management/clinical-trials"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Zepbound (tirzepatide) in chronic weight management: Clinical trials questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Zepbound](https://uspl.lilly.com/zepbound/zepbound.html#pi)

Questions that apply to every indication of Zepbound are on [Zepbound (tirzepatide), all indications](https://www.evicenter.com/medical-information/zepbound).

## Study results

<a id="zepbound-surmount1-weight-loss"></a>

### How much weight do people lose on Zepbound (SURMOUNT-1)?

> “Study 1 (NCT04184622) was a 72-week trial that enrolled 2,539 adult patients with obesity (BMI ≥30 kg/m2), or with overweight (BMI 27 to <30 kg/m2) and at least one weight-related comorbid condition, such as dyslipidemia, hypertension, obstructive sleep apnea, or CV disease; patients with type 2 diabetes mellitus were excluded. Patients were randomized in a 1:1:1:1 ratio to once weekly fixed dosage of ZEPBOUND 5 mg, ZEPBOUND 10 mg, ZEPBOUND 15 mg, or placebo, with an escalation period of up to 20 weeks followed by the maintenance period.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Study%201%20%28NCT04184622%29%20was%20a,followed%20by%20the%20maintenance%20period.)

> “Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight
>
> Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to study drug.
>
>
>
>
> a The intention-to-treat population includes all randomly assigned patients. For Study 1 at Week 72, body weight was missing for 21.6%, 10.2%, 10.5%, and 9.4% of patients randomly assigned to placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, respectively. For Study 2 at Week 72, body weight was missing for 11.1%, 4.8%, and 8.4% of patients randomly assigned to placebo, ZEPBOUND 10 mg, and 15 mg, respectively. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19).
>
>
>
>
> b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
>
>
>
>
> c Analyzed using logistic regression adjusted for baseline value.
>
>
>
>
> d p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate.
>
>
>
>
> e Not controlled for type I error rate.
>
>
> 	Study 1	Study 2
>
> Intention-to-Treat (ITT) Populationa	
> Placebo
> N = 643	ZEPBOUND
> 5 mg
> N = 630	ZEPBOUND
> 10 mg
> N = 636	ZEPBOUND
> 15 mg
> N = 630	
> Placebo
> N = 315	ZEPBOUND
> 10 mg
> N = 312	ZEPBOUND
> 15 mg
> N = 311
> Body Weight							
>      Baseline mean (kg)	104.8	102.9	105.8	105.6	101.7	100.9	99.6
>      % Change from baselineb	-3.1	-15.0	-19.5	-20.9	-3.2	-12.8	-14.7
>      % Difference from placebob
>       (95% CI)		-11.9
> (-13.4, -10.4)d	-16.4
> (-17.9, -14.8)d	-17.8
> (-19.3, -16.3)d		-9.6
> (-11.1, -8.1)d	-11.6
> (-13.0, -10.1)d”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Table%202%3A%20Changes%20in%20Body,%28%2D13.0%2C%20%2D10.1%29d)

> “The proportions of patients who discontinued study drug in Study 1 were 14.3%, 16.4%, and 15.1% for the 5 mg, 10 mg, and 15 mg ZEPBOUND-treated groups, respectively, and 26.4% for the placebo-treated group.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=The%20proportions%20of%20patients%20who,26.4%25%20for%20the%20placebo%2Dtreated%20group.)

Note: Table 2 columns are, for Study 1, placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, then, for Study 2, placebo, ZEPBOUND 10 mg, and 15 mg. Study 1 of the Prescribing Information has the same duration and enrollment (72 weeks, 2,539 patients) as SURMOUNT-1 on the Zepbound HCP site.

<a id="zepbound-percent-achieving"></a>

### Zepbound: how many people lose 5%, 10%, 15%, or 20% of their weight?

> “Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Table%202%3A%20Changes%20in%20Body,Patients%20with%20Obesity%20or%20Overweight)

> “Study 2 (NCT04657003) was a 72-week trial that enrolled 938 adult patients with BMI ≥27 kg/m2 and type 2 diabetes mellitus.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Study%202%20%28NCT04657003%29%20was%20a,and%20type%202%20diabetes%20mellitus.)

> “Intention-to-Treat (ITT) Populationa	
> Placebo
> N = 643	ZEPBOUND
> 5 mg
> N = 630	ZEPBOUND
> 10 mg
> N = 636	ZEPBOUND
> 15 mg
> N = 630	
> Placebo
> N = 315	ZEPBOUND
> 10 mg
> N = 312	ZEPBOUND
> 15 mg
> N = 311”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Intention%2Dto%2DTreat%20%28ITT%29%20Populationa,N%20%3D%20311)

> “% of Patients losing ≥5% body weight	34.5	85.1	88.9	90.9	32.5	79.2	82.8
>      % Difference from placebo
>       (95% CI)		50.3
> (44.3, 56.2)c,d	54.6
> (49.1, 60.0)c,d	56.4
> (50.9, 62.0)c,d		46.8
> (39.5, 54.1)c,d	50.4
> (43.1, 57.8)c,d
> % of Patients losing ≥10% body weight	18.8	68.5	78.1	83.5	9.5	60.5	64.8
>      % Difference from placebo
>       (95% CI)		49.3
> (43.6, 54.9)c,e	59.5
> (54.2, 64.9)c,d	64.8
> (59.6, 70.1)c,d		51.0
> (44.4, 57.7)c,d	55.3
> (48.6, 62.0)c,d
> % of Patients losing ≥15% body weight	8.8	48.0	66.6	70.6	2.7	39.7	48.0
>      % Difference from placebo
>       (95% CI)		38.7
> (33.6, 43.7)c,e	58.1
> (53.2, 63.0)c,d	62.0
> (57.2, 66.8)c,d		37.0
> (31.1, 42.9)c,d	45.4
> (39.4, 51.4)c,d
> % of Patients losing ≥20% body weight	3.1	30.0	50.1	56.7	1.0	21.5	30.8
>      % Difference from placebo
>       (95% CI)		26.6
> (22.4, 30.7)c,e	47.3
> (42.7, 51.9)c,d	53.8
> (49.3, 58.3)c,d		20.5
> (15.7, 25.4)c,d	29.7
> (24.3, 35.0)c,d”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=of%20Patients%20losing%20%E2%89%A55%25%20body,%2824.3%2C%2035.0%29c%2Cd)

> “c Analyzed using logistic regression adjusted for baseline value.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=c%20Analyzed%20using%20logistic%20regression%20adjusted%20for%20baseline%20value.)

> “d p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=d%20p%2Dvalue%3C0.001%20%28unadjusted%202%2Dsided%29%20for%20superiority%2C%20controlled%20for%20type%20I%20error%20rate.)

> “e Not controlled for type I error rate.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=e%20Not%20controlled%20for%20type%20I%20error%20rate.)

Note: Table 2 columns are, for Study 1, placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, then, for Study 2, placebo, ZEPBOUND 10 mg, and 15 mg. Studies 1 and 2 have the same duration and enrollment as SURMOUNT-1 (2,539 patients) and SURMOUNT-2 (938 patients) on the Zepbound HCP site.

<a id="zepbound-lose-25-percent"></a>

### How many people on Zepbound lose 25% or more of their body weight?

> “Bar graph showing the percentage of adults who had ≥25% weight loss in the SURMOUNT-1 trial (Zepbound 5 mg, 10 mg, and 15 mg vs placebo at 72 weeks). There were 630, 636, 630, and 643 total adults for Zepbound 5 mg, 10 mg, 15 mg, and placebo, respectively. The mean baseline weights were 226.8 lb for Zepbound 5 mg, 233.3 lb for Zepbound 10 mg, 232.8 lb for Zepbound 15 mg, and 231.0 lb for placebo. The percentage of adults achieving ≥25% weight loss was 15.3% for Zepbound 5 mg, 32.3% for Zepbound 10 mg, and 36.2% for Zepbound 15 mg vs 1.5% for placebo.”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Bar%20graph%20showing%20the%20percentage,mg%20vs%201.5%25%20for%20placebo.)

On the page, select: Show description

> “This was an exploratory endpoint and was not adjusted for type I error.<sup>2</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=This%20was%20an%20exploratory%20endpoint%20and%20was%20not%20adjusted%20for%20type%20I)

> “Studied in adults with obesity (BMI of ≥30 kg/m<sup>2</sup>), or with overweight (BMI of ≥27 kg/m<sup>2</sup>) with at least 1 weight-related comorbidity, excluding type 2 diabetes.<sup>1</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=type%20I%20error.2-,Studied%20in%20adults%20with%20obesity%20%28BMI%20of%20%E2%89%A530%20kg%2Fm2%29%2C%20or,comorbidity%2C%20excluding%20type%202%20diabetes.1)

> “In a separate weight-reduction study of adults with a BMI of ≥27 kg/m<sup>2</sup> and type 2 diabetes, percent of patients losing ≥25% Zepbound 10 mg and Zepbound 15 mg was 9% and 15%, respectively vs <1% for placebo. Mean baseline weights were 222.4 lb (10 mg), 219.6 lb (15 mg), and 224.2 lb (placebo). This was an exploratory endpoint not controlled for type 1 error.<sup>7</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=and%20type%202%20diabetes%2C%20percent,not%20controlled%20for%20type%201)

<a id="zepbound-surmount2-type-2-diabetes"></a>

### Zepbound in type 2 diabetes: how much weight do people lose (SURMOUNT-2)?

Applies to: Weight reduction in adults with overweight or obesity and type 2 diabetes (SURMOUNT-2)

> “Study 2 (NCT04657003) was a 72-week trial that enrolled 938 adult patients with BMI ≥27 kg/m2 and type 2 diabetes mellitus. Patients included in the trial had HbA1c 7-10% and were treated with either diet and exercise alone, or any oral anti-hyperglycemic agent except dipeptidyl peptidase-4 (DPP-4) inhibitors or GLP-1 receptor agonists. Patients who were taking insulin or injectable GLP-1 receptor agonists for type 2 diabetes mellitus were excluded. Patients were randomized in a 1:1:1 ratio to once weekly fixed dosage of ZEPBOUND 10 mg, ZEPBOUND 15 mg, or placebo with an escalation period of up to 20 weeks followed by the maintenance period.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Study%202%20%28NCT04657003%29%20was%20a,followed%20by%20the%20maintenance%20period.)

> “In a separate weight-reduction study of adults with a BMI of ≥27 kg/m<sup>2</sup> and type 2 diabetes, the overall percentage change in body weight from baseline at 72 weeks was -12.8% (10 mg), -14.7% (15 mg), and -3.2% (placebo). Mean baseline weights were 222.4 lb (10 mg), 219.6 lb (15 mg), and 224.2 lb (placebo).<sup>1,3</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=In%20a%20separate%20weight%2Dreduction%20study,%2815%20mg%29%2C%20and%20224.2%20lb)

> “Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Table%202%3A%20Changes%20in%20Body,Patients%20with%20Obesity%20or%20Overweight)

> “Intention-to-Treat (ITT) Populationa	
> Placebo
> N = 643	ZEPBOUND
> 5 mg
> N = 630	ZEPBOUND
> 10 mg
> N = 636	ZEPBOUND
> 15 mg
> N = 630	
> Placebo
> N = 315	ZEPBOUND
> 10 mg
> N = 312	ZEPBOUND
> 15 mg
> N = 311
> Body Weight							
>      Baseline mean (kg)	104.8	102.9	105.8	105.6	101.7	100.9	99.6
>      % Change from baselineb	-3.1	-15.0	-19.5	-20.9	-3.2	-12.8	-14.7
>      % Difference from placebob
>       (95% CI)		-11.9
> (-13.4, -10.4)d	-16.4
> (-17.9, -14.8)d	-17.8
> (-19.3, -16.3)d		-9.6
> (-11.1, -8.1)d	-11.6
> (-13.0, -10.1)d”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Intention%2Dto%2DTreat%20%28ITT%29%20Populationa,%28%2D13.0%2C%20%2D10.1%29d)

> “The proportions of patients who discontinued study drug in Study 2 were 9.3% and 13.8% for the 10 mg and 15 mg ZEPBOUND-treated groups, respectively, and 14.9% for the placebo-treated group.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=the%20placebo%2Dtreated%20group.-,The%20proportions%20of%20patients%20who%20discontinued%20study%20drug%20in%20Study,14.9%25%20for%20the%20placebo%2Dtreated%20group.)

Note: In the Table 2 rows, the last three columns are Study 2: placebo, ZEPBOUND 10 mg, and 15 mg. Study 2 of the Prescribing Information has the same duration and enrollment (72 weeks, 938 patients) as SURMOUNT-2 on the Zepbound HCP site.

<a id="zepbound-surmount3-after-lifestyle"></a>

### Does Zepbound add weight loss after an intensive lifestyle program (SURMOUNT-3)?

> “Study 3 (NCT04657016) was an 84-week trial with a 12-week intensive lifestyle intervention lead-in period (Week -12 to Week 0), followed by a 72-week randomized treatment period of ZEPBOUND versus placebo (Week 0 to Week 72) with a standard lifestyle intervention. Only patients who lost ≥5% body weight during the 12-week intensive lifestyle lead-in period entered the 72-week randomized treatment period. The trial initially enrolled 806 adult patients (aged 18 years and older) with obesity (BMI ≥30 kg/m2), or with overweight (BMI 27 to <30 kg/m2) and at least one weight-related comorbid condition, such as dyslipidemia, hypertension, obstructive sleep apnea, or CV disease; patients with type 2 diabetes mellitus were excluded.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Study%203%20%28NCT04657016%29%20was%20an,2%20diabetes%20mellitus%20were%20excluded.)

> “At the end of the 12-week intensive lifestyle intervention lead-in, for patients who subsequently entered the randomized treatment period (n=579), the average body weight loss due to lifestyle was 6.9% (Week -12 to Week 0).”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=At%20the%20end%20of%20the%2012%2Dweek%20intensive%20lifestyle%20intervention%20lead%2Din%2C,%28Week%20%2D12%20to%20Week%200%29.)

> “Table 4: Changes in Body Weight After 12-Week Intensive Lifestyle Intervention Lead-In Followed by Randomized Treatment and a Standard Lifestyle Intervention (Study 3) in Patients with Obesity or Overweight
>
> Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; MTD = maximum tolerated dose; N = number of patients randomly assigned to study drug.
>
>
>
>
> a The intent-to-treat population included only randomized patients with ≥5% weight loss at Week 0 after 12 weeks of intensive lifestyle intervention. During the 12-week lead-in period, 227 of 806 patients (28.2%) discontinued from the study. Of these 141 (17.5%) discontinued due to not achieving the randomization criteria of ≥5% weight reduction.
>
>
>
>
> b The intent-to-treat population includes all randomly assigned patients. For Study 3 at Week 72, body weight was missing for 23.6% and 8.7% of patients randomly assigned to placebo and ZEPBOUND MTD (10 or 15 mg). The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19).
>
>
>
>
> c Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
>
>
>
>
> d Analyzed using logistic regression adjusted for baseline value.
>
>
>
>
> e p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate.
>
>
> 	Study 3
> N = 579a
> Body Weight	
>      Mean (kg) at Week -12	109.5
> Intention-to-Treat (ITT) Populationa,b	
> Placebo
> N = 292	ZEPBOUND
> MTD (10 mg or 15 mg)
> N = 287
> Body Weight		
>      Mean (kg) at Week 0	101.3	102.5
>      % Change from randomization at Week 72c	2.5	-18.4
>      % Difference from placebo, at Week 72c
>       (95% CI)		-20.8
> (-23.2, -18.5)e
>      % of Patients losing ≥5% body weight	16.5	87.5
>      % Difference from placebo
>       (95% CI)		71.1
> (63.6, 78.5)d,e
>      % of Patients losing ≥10% body weight	8.9	76.7
>      % Difference from placebo
>       (95% CI)		67.9
> (60.7, 75.1)d,e
>      % of Patients losing ≥15% body weight	4.2	65.4
>      % Difference from placebo
>       (95% CI)		61.3
> (54.5, 68.1)d,e
>      % of Patients losing ≥20% body weight	2.2	44.7
>      % Difference from placebo
>       (95% CI)		42.6
> (36.0, 49.1)d,e”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Table%204%3A%20Changes%20in%20Body,%2836.0%2C%2049.1%29d%2Ce)

> “The proportions of patients who discontinued study drug after randomization were 21.3% for the ZEPBOUND-treated group and 30.5% for the placebo-treated group.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=The%20proportions%20of%20patients%20who%20discontinued%20study%20drug%20after,30.5%25%20for%20the%20placebo%2Dtreated%20group.)

Note: Table 4 columns are placebo and ZEPBOUND MTD (10 mg or 15 mg), in that order. Study 3 of the Prescribing Information has the same design and enrollment (806 enrolled, 579 randomized) as SURMOUNT-3 on the Zepbound HCP site.

<a id="zepbound-weight-regain-after-stopping"></a>

### Do people regain weight after stopping Zepbound (SURMOUNT-4)?

> “Study 4 (NCT04660643) was an 88-week randomized withdrawal trial in which all patients received open-label ZEPBOUND during a 36-week lead-in period, followed by randomization to either continue ZEPBOUND or switch to placebo for 52 weeks.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Study%204%20%28NCT04660643%29%20was%20an,to%20placebo%20for%2052%20weeks.)

> “After open-label ZEPBOUND treatment, randomized patients (n=670) had an average body weight loss of 20.9% (Week 0 to Week 36).”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=After%20open%2Dlabel%20ZEPBOUND%20treatment%2C%20randomized,%28Week%200%20to%20Week%2036%29.)

> “Table 6: Changes in Body Weight After 36-Week Open-Label Treatment Followed by Randomized Withdrawal (Study 4) in Patients with Obesity or Overweight
>
> Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; MTD = maximum tolerated dose; N = number of patients randomly assigned to study drug.
>
>
>
>
> a The intent-to-treat population included all randomly assigned patients and did not include 113 patients who were enrolled but not randomized. At Week 88, body weight was missing for 13.7% and 7.5% of patients randomly assigned to placebo and ZEPBOUND MTD (10 or 15 mg), respectively. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19).
>
>
>
>
> b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
>
>
>
>
> c p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate.
>
>
> 	Study 4
> N=670a
> Body Weight	
>      Mean at Week 0 (kg)	107.3
> Intention-to-Treat (ITT) Populationa	Placebo
> N=335	ZEPBOUND
> (MTD 10 mg or 15 mg)
> N=335
> Body Weight		
>      Mean at Week 36 (kg)	85.8	84.6
>      % change from Week 36 at Week 88b	14.0	-5.5
>      % difference from placebo at Week 88
>       (95% CI)b		-19.4
> (-21.2, -17.7)c”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Table%206%3A%20Changes%20in%20Body,%28%2D21.2%2C%20%2D17.7%29c)

> “The proportions of patients who discontinued study drug after randomization at Week 36 were 10.4% for the ZEPBOUND-treated group and 17.9% for the placebo-treated group.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=in%20Study%204.-,The%20proportions%20of%20patients%20who%20discontinued%20study%20drug%20after%20randomization,17.9%25%20for%20the%20placebo%2Dtreated%20group.)

> “<sup>a</sup>Hybrid imputation least-square mean values at week 88 were -25.3% for Zepbound MTD and -9.9% for those who switched to placebo at week 36.”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=imputation%20least%2Dsquare%20mean%20values%20at,to%20placebo%20at%20week%2036.)

> “Change from Week 0 was not a primary endpoint in Study 4.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Change%20from%20Week%200%20was%20not%20a%20primary%20endpoint%20in%20Study%204.)

Note: Table 6 columns are placebo and ZEPBOUND MTD (10 mg or 15 mg), in that order. The week 88 values from week 0 are from the clinical data page of the Zepbound HCP site. Study 4 of the Prescribing Information has the same design and enrollment (783 enrolled, 670 randomized) as SURMOUNT-4.

<a id="zepbound-vs-wegovy"></a>

### Zepbound vs Wegovy: which causes more weight loss (SURMOUNT-5)?

> “An open-label, head-to-head trial comparing Zepbound® (10 mg or 15 mg) to Wegovy® (semaglutide) injection (1.7 mg or 2.4 mg)<sup>14</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=An%20open%2Dlabel%2C%20head%2Dto%2Dhead%20trial%20comparing,injection%20%281.7%20mg%20or%202.4)

> “Line graph showing the percentage change in body weight from baseline to week 72 in the SURMOUNT-5 trial (Zepbound MTD [10 or 15 mg] vs Wegovy MTD [1.7 or 2.4 mg]). There were 374 total adults for Zepbound and 376 total adults for Wegovy. The percentage change in body weight at week 72 was -20.2% (-50.3 lbs) for Zepbound vs -13.7% (-33.1 lbs) for Wegovy.”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Line%20graph%20showing%20the%20percentage%20change%20in%20body%20weight%20from,%2D13.7%25%20%28%2D33.1%20lbs%29%20for%20Wegovy.)

On the page, select: Show description

> “<sup>a</sup>P<0.001 for superiority of Zepbound vs Wegovy, controlled for type I error.<sup>14</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=for%20superiority%20of%20Zepbound%20vs%20Wegovy%2C%20controlled%20for%20type%20I)

> “mITT population includes all randomly assigned participants exposed to at least 1 dose of study intervention. The missing values were imputed using retrieved dropouts from the same treatment group. Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.<sup>14</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=mITT%20population%20includes%20all%20randomly,baseline%20value%20and%20other%20stratification)

> “Studied in a randomized, open-label, phase 3b trial of adults who had obesity (BMI ≥30 kg/m<sup>2</sup>), or overweight (BMI ≥27 kg/m<sup>2</sup>) with at least 1 weight-related comorbidity, excluding type 2 diabetes. The study included a 2-week screening period and a 72-week treatment period. Mean baseline weight was 248.4 lb for Zepbound MTD (10 mg or 15 mg) and 250.0 lb for Wegovy MTD (1.7 mg or 2.4 mg).<sup>14,16</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Studied%20in%20a%20randomized%2C%20open%2Dlabel%2C,MTD%20%281.7%20mg%20or%202.4)

> “Wegovy 7.2 mg was not evaluated in this study and has since been approved.”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Wegovy%207.2%20mg%20was%20not,and%20has%20since%20been%20approved.)

> “Limitations of an open-label study may be related to a bias in evaluation of the outcomes, efficacy and/or safety, and the study did not have a comparison with placebo.”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Limitations%20of%20an%20open%2Dlabel%20study,have%20a%20comparison%20with%20placebo.)

Note: SURMOUNT-5 results are from the clinical data page of the Zepbound HCP site, which cites Aronne et al., N Engl J Med 2025; the Zepbound Prescribing Information does not describe this trial.

<a id="zepbound-maintain-lower-dose"></a>

### Is Zepbound weight loss maintained at 5 mg or after stopping (SURMOUNT-MAINTAIN)?

> “Studied in a randomized, phase 3b trial of adults with obesity (BMI ≥30 kg/m<sup>2</sup>), or overweight (BMI ≥27 kg/m<sup>2</sup>) with at least 1 weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), excluding diabetes. This study included a 2-week screening period, followed by a 60-week, open-label weight-loss period with participants receiving Zepbound MTD (10 mg or 15 mg), before being randomized 3:3:2 to continue receiving Zepbound MTD (10 mg or 15 mg), reduce the dose to Zepbound 5 mg, or switch to placebo from week 60 to week 112. The overall mean baseline weight was 250.9 lb.<sup>18,19</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Studied%20in%20a%20randomized%2C%20phase,mean%20baseline%20weight%20was%20250.9)

> “Randomization at week 60 required participants to tolerate at least the 10 mg dose during the weight-loss period and to achieve a ≥5% reduction in body weight.<sup>18</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Randomization%20at%20week%2060%20required,a%20%E2%89%A55%25%20reduction%20in%20body)

> “Line graph showing the efficacy estimand for the primary endpoint of percentage change in body weight from week 0 to week 112. From week 0 to week 60, the open-label weight-loss period, all adults (n=441) received open-label Zepbound maximum tolerated dose (MTD) (10 mg or 15 mg). At week 60 through week 112, the weight maintenance period, adults were randomized to receive Zepbound MTD, have their dose reduced to Zepbound 5 mg, or switch to placebo. The week 112 data are represented by treatment regimen estimand. Adults receiving Zepbound MTD (n=138) experienced a -21.9% (-54.2 lb) reduction in body weight from baseline to week 112. Adults who had their dose reduced to Zepbound 5 mg (n=142) experienced a -16.6% (-41.4 lb) reduction in body weight at week 112. Adults who switched to placebo (n=90) experienced a -9.9% (-24.9 lb) reduction in body weight at week 112. From week 60 to week 84, rescue Zepbound was not allowed. From week 84 to week 112, rescue Zepbound was allowed. The mean baseline weight was 250.9 lb.”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Line%20graph%20showing%20the%20efficacy,baseline%20weight%20was%20250.9%20lb.)

On the page, select: Show description

> “The graph represents EE, the week 112 numbers indicate TRE.<sup>18</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=The%20graph%20represents%20EE%2C%20the%20week%20112%20numbers%20indicate)

> “mTRE: Average treatment effect for randomized participants based on the mITT population who stayed in the study regardless of treatment discontinuation and initiation of other obesity medications. This estimand also assumes that participants who had bariatric surgery or another weight-loss procedure or took rescue tirzepatide would not have received any additional improvement from their randomized study treatment.”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=mTRE%3A%20Average%20treatment%20effect%20for,from%20their%20randomized%20study%20treatment.)

> “Results reflect the modified treatment regimen estimand with worst observation carried forward imputation applied to data after rescue.<sup>18</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Results%20reflect%20the%20modified%20treatment,imputation%20applied%20to%20data%20after)

> “Rescue Zepbound was made available starting at week 84 for participants in all 3 treatment groups if ≥50% of the initial weight reduction they achieved during weeks 0-60 was regained. Randomization blinding was maintained despite receiving rescue therapy. 11 participants in the Zepbound MTD group, 35 participants in the Zepbound 5 mg group, and 60 participants in the placebo group received rescue Zepbound beginning at week 84.<sup>18</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Rescue%20Zepbound%20was%20made%20available,rescue%20Zepbound%20beginning%20at%20week)

> “<sup>a</sup>The primary endpoint was controlled for type I error.<sup>18</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=primary%20endpoint%20was%20controlled%20for%20type%20I)

> “SURMOUNT-MAINTAIN was conducted in adults with obesity who tolerated at least tirzepatide 10 mg and achieved ≥5% bodyweight reduction during the open-label Weight-Loss Period; therefore, results may not be generalizable to all patients.”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=SURMOUNT%2DMAINTAIN%20was%20conducted%20in%20adults,be%20generalizable%20to%20all%20patients.)

Note: SURMOUNT-MAINTAIN results are from the clinical data page of the Zepbound HCP site, which cites Horn et al., Lancet 2026; the Zepbound Prescribing Information does not describe this trial.

<a id="zepbound-maintain-percent-kept-off"></a>

### How much weight loss do people keep off on Zepbound (SURMOUNT-MAINTAIN)?

> “Bar graph showing the key secondary endpoint of percentage maintenance of body weight reduction. Participants taking Zepbound MTD (10 mg or 15 mg) (n=116) maintained 96.5% of their body weight reduction from the weight loss period. Participants who reduced their dose to Zepbound 5 mg (n=118) maintained 67.9% of their body weight reduction from the weight loss period. Participants who switched to placebo (n=76) maintained 42.8% of their body weight reduction from the weight loss period.”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Bar%20graph%20showing%20the%20key,of%20their%20body%20weight%20reduction%20from%20the%20weight%20loss%20period.)

On the page, select: Show description

> “Additional Key Secondary Endpoint: 77.5% of participants on Zepbound MTD (10 mg or 15 mg), 42.4% on Zepbound 5 mg, and 10.4% on placebo maintained ≥80% of the body weight reduction achieved during the 60-week open-label weight-loss period at Week 112 among those who reached a body weight plateau.<sup>18a</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Additional%20Key%20Secondary%20Endpoint%3A%2077.5%25,who%20reached%20a%20body%20weight)

> “<sup>a</sup>The key secondary endpoints were controlled for type I error.<sup>18</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=key%20secondary%20endpoints%20were%20controlled%20for%20type%20I)

> “*Body weight plateau was defined as a <5% body weight change between week 48 and week 60.<sup>18</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=%2ABody%20weight%20plateau%20was%20defined,between%20week%2048%20and%20week)

Note: The maintenance percentages are among participants who reached a body weight plateau during the 60-week open-label weight-loss period. SURMOUNT-MAINTAIN is not described in the Zepbound Prescribing Information.

<a id="zepbound-older-adults"></a>

### How much weight do adults 65 and older lose on Zepbound?

Applies to: Adults aged 65 and older with obesity, or with overweight and at least one weight-related comorbid condition

> “Mean percentage change in body weight from baseline to week 72 for a total of 152 adults were -14.1% with Zepbound 5 mg (n=52), -18.0% with Zepbound 10 mg (n=31), and -20.3% with Zepbound 15 mg (n=35), compared to -4.8% with placebo (n=34).<sup>8</sup>”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Mean%20percentage%20change%20in%20body%20weight%20from%20baseline%20to%20week%2072%20for,-a%20total%20of)

> “This was a prespecified sub-group analysis among the secondary endpoints of the SURMOUNT-1 study. The analyses were not adjusted for type I error.”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=This%20was%20a%20prespecified,adjusted%20for%20type%20I%20error.)

> “In a pool of two fixed dose ZEPBOUND clinical studies for weight reduction (Study 1 and Study 2), 226 (9%) ZEPBOUND-treated patients were 65 years of age or older, and 13 (0.5%) ZEPBOUND-treated patients were 75 years of age or older at baseline.
>
> No overall differences in safety or effectiveness of ZEPBOUND have been observed between patients 65 years of age and older and younger adult patients.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=In%20a%20pool%20of%20two%20fixed,older%20and%20younger%20adult%20patients.)

<a id="zepbound-blood-pressure-cholesterol"></a>

### Does Zepbound lower blood pressure, cholesterol, and triglycerides?

> “Table 3: Changes in Anthropometry and Cardiometabolic Parameters at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight
>
> Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to study drug.
>
>
>
>
> a The intention-to-treat population includes all randomly assigned patients. The missing values were imputed by a hybrid approach using retrieved dropouts from the same treatment group (if missing not due to COVID-19) or using all non-missing data assuming missing at random (for missing solely due to COVID-19).
>
>
>
>
> b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.
>
>
>
>
> c Analyzed using log-transformed data.
>
>
>
>
> d p-value<0.001 (unadjusted 2-sided) for superiority, controlled for type I error rate.
>
>
>
>
> e Not controlled for type I error rate.
>
>
>
>
> f Least-squares mean from mixed model for repeated measures adjusted for baseline value and other stratification factors.
>
>
>
>
> g Baseline value is the geometric mean.
>
>
> 	Study 1	Study 2
>
> Intention-to-Treat (ITT) Populationa	
> Placebo
> N = 643	ZEPBOUND
> 5 mg
> N = 630	ZEPBOUND
> 10 mg
> N = 636	ZEPBOUND
> 15 mg
> N = 630	
> Placebo
> N = 315	ZEPBOUND
> 10 mg
> N = 312	ZEPBOUND
> 15 mg
> N = 311
> Waist Circumference (cm)							
>      Baseline mean	114.0	113.2	114.8	114.4	116.0	114.2	114.6
>      Change from baselineb	-4.0	-14.0	-17.7	-18.5	-3.3	-10.8	-13.1
>      Difference from
>      placebob (95% CI)		-10.1
> (-11.6, -8.6)e	-13.8
> (-15.2, -12.3)d	-14.5
> (-15.9, -13.0)d		-7.4
> (-9.0, -5.9)d	-9.8
> (-11.2, -8.3)d
> Systolic Blood Pressure (mmHg)							
>      Baseline mean	122.9	123.6	123.8	123.0	131.0	130.6	130.0
>      Change from baselineb	-1.0	-6.6	-7.7	-7.4	-1.2	-5.6	-7.1
>      Difference from
>      placebob (95% CI)		-5.6
> (-7.2, -3.9)e	-6.7
> (-8.4, -5.0)e	-6.4
> (-8.0, -4.8)e		-4.4
> (-6.7, -2.1)e	-5.9
> (-8.3, -3.6)e
> Diastolic Blood Pressure (mmHg)							
>      Baseline mean	79.6	79.3	79.9	79.3	79.4	80.2	79.7
>      Change from baselineb	-0.8	-4.9	-5.0	-4.5	-0.3	-2.1	-2.9
>      Difference from
>      placebob (95% CI)		-4.1
> (-5.2, -3.0)e	-4.2
> (-5.3, -3.0)e	-3.7
> (-4.8, -2.7)e		-1.8
> (-3.3, -0.4)e	-2.7
> (-4.2, -1.2)e
> Pulse Rate (beats per minute)							
>      Baseline mean	72.9	72.4	71.8	72.4	74.8	75.9	75.6
>      Change from baselinef	0.1	0.6	2.3	2.6	-0.5	0.6	1.0
>      Difference from
>      placebof (95% CI)		0.5
> (-0.5, 1.5)e	2.2
> (1.2, 3.2)e	2.5
> (1.5, 3.4)e		1.2
> (-0.1, 2.5)e	1.5
> (0.2, 2.8)e
> Total Cholesterol (mg/dL)							
>      Baseline meang	187.5	187.1	190.6	187.5	174.9	173.9	167.0
>      % change from
>      baselineb	-1.8	-3.8	-4.4	-6.3	2.8	-2.8	-1.0
>      Relative difference
>      from placebob (95% CI)		-2.1
> (-4.5, 0.4)c,e	-2.7
> (-5.1, -0.2)c,e	-4.6
> (-6.8, -2.2)c,e		-5.5
> (-8.7, -2.2)c,e	-3.8
> (-7.1, -0.3)c,e
> LDL Cholesterol (mg/dL)							
>      Baseline meang	109.4	108.7	112.3	109.3	92.4	90.5	85.7
>      % change from
>      baselineb	-1.7	-4.6	-5.6	-7.1	7.4	1.8	4.1
>      Relative difference
>      from placebob (95% CI)		-2.9
> (-6.6, 0.9)c,e	-4.0
> (-7.5, -0.5)c,e	-5.5
> (-8.9, -2.0)c,e		-5.2
> (-10.1, 0.1)c,e	-3.0
> (-8.4, 2.6)c,e
> HDL Cholesterol (mg/dL)							
>      Baseline meang	46.6	47.6	47.6	47.6	42.7	43.8	42.2
>      % change from
>      baselineb	-0.7	6.9	9.2	8.0	0.2	8.2	9.7
>      Relative difference
>      from placebob (95% CI)		7.7
> (4.6, 10.8)c,e	9.9
> (6.7, 13.2)c,e	8.7
> (5.7, 11.8)c,e		8.0
> (4.2, 11.8)c,e	9.5
> (5.6, 13.5)c,e
> Non-HDL Cholesterol (mg/dL)							
>      Baseline meang	138.3	137.0	140.4	137.5	129.6	127.2	121.9
>      % change from
>      baselineb	-2.3	-8.0	-9.4	-11.7	3.7	-6.6	-5.2
>      Relative difference
>      from placebob (95% CI)		-5.8
> (-8.9, -2.6)c,e	-7.2
> (-10.3, -4.1)c,e	-9.6
> (-12.4, -6.6)c,e		-9.9
> (-14.1, -5.6)c,e	-8.5
> (-12.9, -4.0)c,e
> Triglycerides (mg/dL)							
>      Baseline meang	130.8	128.7	125.7	128.1	165.0	158.8	158.5
>      % change from
>      baselineb	-5.6	-21.2	-23.8	-29.1	-3.3	-27.1	-27.3
>      Relative difference
>      from placebob (95% CI)		-16.5
> (-21.2, -11.4)c,e	-19.3
> (-23.9, -14.4)c,e	-24.9
> (-29.1, -20.4)c,e		-24.6
> (-30.0, -18.7)c,e	-24.8
> (-30.3, -18.9)c,e”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Table%203%3A%20Changes%20in%20Anthropometry,%28%2D30.3%2C%20%2D18.9%29c%2Ce)

> “Zepbound is not indicated for hypertension or dyslipidemia.”

Source: [ZEPBOUND: Clinical Data, Safety & Study Design, captured 2026-11-12](https://zepbound.lilly.com/hcp/clinical-data-weight#:~:text=Zepbound%20is%20not%20indicated%20for%20hypertension%20or%20dyslipidemia.)

On the page, select: Show description

Note: Table 3 columns are, for Study 1, placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, then, for Study 2, placebo, ZEPBOUND 10 mg, and 15 mg; footnote e marks results not controlled for type I error. The clinical data page of the Zepbound HCP site reports HDL cholesterol, systolic blood pressure, and triglycerides for pooled Zepbound doses in SURMOUNT-1 as controlled for type I error.

## Related pages
- [Medical information: Zepbound (tirzepatide): Chronic weight management](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management)
- [Indication](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management/access-and-coverage)
